ozapram 10mg film coated tablets
remedica ltd (0000003171) aharnon str., lemesos, 3056 - olanzapine - film coated tablets - 10mg - olanzapine (8000001532) 10mg - olanzapine
ozapram 20mg film coated tablets
remedica ltd (0000003171) aharnon str., lemesos, 3056 - olanzapine - film coated tablets - 20mg - olanzapine (8000001532) 20mg - olanzapine
ozapram 5mg film coated tablets
remedica ltd (0000003171) aharnon str., lemesos, 3056 - olanzapine - film coated tablets - 5mg - olanzapine (8000001532) 5mg - olanzapine
urorec
recordati ireland ltd - σιλοδισίνη - Υπερπλασία του προστάτη - Ουρολογικά - Η θεραπεία των σημείων και συμπτωμάτων της καλοήθους υπερπλασίας του προστάτη (bph).
silodyx
recordati ireland ltd - σιλοδισίνη - Υπερπλασία του προστάτη - Ουρολογικά - Η θεραπεία των σημείων και συμπτωμάτων της καλοήθους υπερπλασίας του προστάτη (bph).
silodosin recordati
recordati ireland ltd - σιλοδισίνη - Υπερπλασία του προστάτη - urologicals, Άλφα-εκφύτων ανταγωνιστές - Θεραπεία των σημείων και συμπτωμάτων της καλοήθους υπερπλασίας του προστάτη (ΚΥΠ) σε ενήλικες άνδρες.
minirin 0.2mg tablets
ferring hellas mepe (0000010966) 2 karagiorgi servias str., athens, 10562 - desmopressin acetate - tablets - 0.2mg - desmopressin acetate (0062357862) 0,2mg - desmopressin
minirin 0.1mg tablets
ferring hellas mepe (0000010966) 2 karagiorgi servias str., athens, 10562 - desmopressin acetate - tablets - 0.1mg - desmopressin acetate (0062357862) 0,1mg - desmopressin
vidaza
bristol-myers squibb pharma eeig - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.